Cleveland Biolabs (CBLI) Reports Q1 Loss of $0.06/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
May 16, 2016 7:30 AM EDTBUFFALO, NY -- (Marketwired) -- 05/16/16 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016.
Cleveland BioLabs reported a net loss, excluding minority interests, of $(0.7) million for the first quarter of 2016, or $(0.06) per share, compared to a net loss of $(3.7) million, or $(1.14) per share, for the first quarter of 2015.
As of March 31, 2016, the Company had $18.0 million in cash, cash equivalents and short-term investments, which, based on the Company's current operational plan, is expected to fund the Company's operating requirements... More
